LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡

Rhea-AI Summary

LifeVantage (Nasdaq: LFVN) has announced expanded clinical trial results for its MindBody GLP-1 System™, showing enhanced effectiveness in natural GLP-1 production. The combined data from trials completed in April 2025 and fall 2024 demonstrated an average increase in GLP-1 of over 200%, up from the previously reported 140%.

The clinical studies revealed significant outcomes including average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds. Key body composition improvements include up to 9% decrease in total body fat, 24% decrease in visceral fat, and 6% increase in skeletal muscle. Notably, 100% of weight lost was from fat, not muscle.

Participants reported substantial behavioral changes, with 95% experiencing decreased sugar cravings and over 85% reporting improved eating habits and reduced hunger. The company also completed an independent 12-week trial of the international formula (MB System) with similar positive results.

Positive

• Clinical trials showed over 200% increase in natural GLP-1 production, significantly higher than previous 140% result
• Average weight loss of 11 pounds in 12 weeks, with some participants losing up to 25 pounds
• Strong body composition improvements including 9% decrease in body fat and 6% increase in skeletal muscle
• High efficacy rates with 95% of participants reporting decreased sugar cravings
• Successful validation of both U.S. and international formulas through independent clinical trials

Negative

• None.

News Market Reaction

+2.94%

4 alerts

+2.94% News Effect

+$5M Valuation Impact

$178M Market Cap

0.6x Rel. Volume

On the day this news was published, LFVN gained 2.94%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $178M at that time.

Data tracked by StockTitan Argus on the day of publication.

Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡

SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the MindBody GLP-1 System™, revealing even more compelling outcomes across a broader participant base.

When researchers combined data from the most recent clinical trial completed in April 2025, with findings from the initial trial conducted in fall 2024, the average increase of GLP-1 improved to over 200% – a significant rise from the previously reported 140%. GLP-1 is a critical hormone that supports appetite regulation, metabolic health, and fat processing. This enhanced result further reinforces the effectiveness of the MindBody GLP-1 System in promoting sustainable, natural wellness through Activation.*‡‡

“These findings validate the effectiveness of our natural approach to stimulating the body’s own production of GLP-1 and other key metabolic hormones,” said Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage. “The MindBody GLP-1 System and living an activated lifestyle produces meaningful, lasting results – helping people manage cravings, improve self-control, and support sustainable metabolic health naturally. We remain committed to delivering evidence-based innovations that empower health from within.*”

Key findings from LifeVantage’s U.S. clinical studies on the MindBody GLP-1 System include:

• Over 200% average increase in GLP-1 over 12 weeks^‡‡
• Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds^‡,‡‡
• Up to 9% decrease in total body fat percentage ^‡,‡‡
• Up to 24% decrease in visceral fat^‡,‡‡
• Up to 9% decrease in subcutaneous fat^‡,‡‡
• Up to 6% increase in skeletal muscle^‡‡
• 100% of weight lost was from fat, not muscle^‡,ΩΩ
  

In addition to these physical results, participants reported notable changes in their relationship with food:

• 95% reported decreased sugar cravings^ΩΩ
• 89% reported decreased fast-food cravings^§§
• 86% reported decreased cravings for salt and soda^§§
• 85% now eat for health instead of emotions^ΩΩ
• 81% reported increased ability to resist snacking^§§
• 89% ate less at meals^§§
• 86% reported feeling less hungry^§§
  

Additionally, LifeVantage completed an independent 12-week human clinical trial of the international formula, known as the MB System, affirming the Company’s commitment to science-backed innovation across global markets. The study was conducted by Lighthouse Research and demonstrated an average increase in GLP-1 production of over 200%^‡‡ along with significant improvements in body composition^‡ and eating behaviors.

To learn more about the clinical trial findings or explore how the MindBody GLP-1 System can fit into your wellness routine, visit www.lifevantage.com.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes, and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*

‡‡ Results based on the averaged data of two 12-week randomized human clinical studies.

ΩΩ Results based on a randomized 12-week human clinical study (Study A, N=56).

§§ Results based on a randomized 12-week human clinical study (Study B, N=107).

‡ Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program. 

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Public Relations Contact:
CerconeBrownCompany
lifevantage@cerconebrown.com

Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com

FAQ

What are the latest clinical trial results for LifeVantage's (LFVN) MindBody GLP-1 System?

The expanded clinical trials showed an average increase in GLP-1 production of over 200%, with participants achieving average weight loss of 11 pounds within 12 weeks and up to 9% decrease in total body fat.

How effective is LifeVantage's MindBody GLP-1 System for weight loss?

Clinical studies showed participants lost an average of 11 pounds in 12 weeks, with some losing up to 25 pounds. Importantly, 100% of weight lost was from fat, not muscle.

What percentage of body fat reduction did LFVN's GLP-1 System achieve in clinical trials?

The clinical trials demonstrated up to 9% decrease in total body fat, 24% decrease in visceral fat, and 9% decrease in subcutaneous fat, while increasing skeletal muscle by 6%.

How does LifeVantage's MindBody GLP-1 System affect food cravings?

According to the clinical trials, 95% of participants reported decreased sugar cravings, 89% reported decreased fast-food cravings, and 86% reported feeling less hungry.

What behavioral changes were reported in LFVN's GLP-1 System clinical trials?

The trials showed that 85% of participants now eat for health instead of emotions, 81% reported increased ability to resist snacking, and 89% ate less at meals.